Research & Development
JanOne implements manufacturing contract for formulation and manufacturing of TV1001SR
7 February 2020 -

It was reported on Thursday that JanOne Inc (NASDAQ: JAN), a pharmaceutical company focused on pain reduction treatments, has begun a contract to manufacture TV1001SR, a treatment for Peripheral Artery Disease.

The product aims to address the underlying cause of Peripheral Artery Disease and associated pain, as a potential alternative to opioids.

Tony Giordano, PhD, JanOne's chief scientific officer, said, 'CoreRx's extensive clinical development experience and capabilities made them a natural choice for phase 2b formulation and manufacturing. As we finalize our clinical protocols for FDA submission and enter the next phase of trials for what we believe could be an effective PAD treatment, CoreRx is a proven partner with exceptional quality controls.'

Login
Username:

Password:


Related Headlines

United Sewing Automation passes test results of NC-manufactured PPE surgical masks

Parnell Pharmaceuticals develops antiviral nasal spray

Luminex secures USD683,500 from BARDA to support COVID-19 multiplex antibody test against future infection

Quadrant Biosciences wins FDA's EUA for new saliva swab for Covid-19 testing

NeuroRx files for FDA's EUA for RLF-100 in the treatment of patients with critical COVID-19

The FDA approves first POC antibody test for COVID-19 using fingerstick blood samples

Vivet Therapeutics and Pfizer Enter into Manufacturing Agreement for Vivet's Investigational Gene Therapy for Wilson Disease

FDA Accepts Supplemental New Drug Application for Pfizer's Xalkori for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma

European Medicines Grants Priority Medicines Designation to bluebird bio's LentiGlobin for Sickle Cell Disease Gene Therapy

FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

Relief Therapeutics seeks US FDA emergency approval for its drug against COVID-19

US FDA to launch Digital Health Center of Excellence within Center for Devices and Radiological Health

US FDA receives Emergency Use Authorisation request for NeuroRx's RLF-100 aviptadil

NeuroRx submits EUA with FDA for RLF-100 (aviptadil) in the treatment of patients with critical COVID-19 and corresponding respiratory failure

Vela Diagnostics' SARS-CoV-2 RT-PCR test v2.0 wins FDA EUA in the US